Printed 16 August 2017
Quanterix announced that it’ll be expanding its single molecule array or Simoa technology platform portfolio to incorporate the brand new Quanterix SR-Plex benchtop instrument.
In the same manner the fully automated HD-1 Analyzer offers recognition and measurement of biomarkers with unparalleled sensitivity, the SR-Plex uses single molecule measurements to evaluate formerly undetectable proteins and may considerably reduce sample volume needs in comparison with alternative approaches, all inside a benchtop format that may be easily integrated with existing automation platforms.
The very first unveiling from the SR-Plex may happen today at generation x Dx Summit in Washington, D.C.
“We are approaching an intersection from the digital health revolution and existence science research. From high-throughput studies with this HD-1 Analyzer to the opportunity of bloodstream-based, point-of-care tools, the unrivaled sensitivity from the Simoa technology helps pharma, academia along with other research labs consider the most significant biological information in existence,” stated Kevin Hrusovsky, Executive Chairman and Ceo at Quanterix.
“In accessory for a smaller sized instrument footprint, the SR-Plex continues to be enhanced for elevated multiplexing abilities, which makes it a user friendly and economical choice for high-sensitivity biomarker analysis, whether proteins or nucleic acids.”
The SR-Plex will participate an entire solution together with a menu in excess of 70 ultra-sensitive protein recognition assays, in addition to a new number of multiplex assays for critical biomarkers, such as the first six-plex Simoa assay for quantitative measurement of elusive inflammatory biomarkers within the bloodstream.
“We are particularly excited the SR-Plex can result in advances in the use of circulating biomarkers, specifically for cancer recognition and treatment. Despite recent innovations in genomic and proteomic technologies, there’s been little advancement in immunological biomarker tests,” ongoing Hrusovsky.
“Simoa’s multiplexing abilities and digital sensitivity provides, the very first time, the opportunity to measure circulating clinically relevant concentrations of immunological mediators, exosomes and miRNA in one benchtop instrument.”
Greater than 145 studies while using Simoa technology happen to be printed in peer-reviewed journals. These studies spans several therapeutic areas for example oncology, neurology, cardiology, inflammation and infectious disease and it has proven that Simoa can identify biomarkers within the subclinical condition, that is valuable for that monitoring of neurodegeneration in illnesses like Alzheimer’s and ms.
Myriad RBM, Corporation., the world’s leading multiplexed immunoassay testing laboratory, will start while using SR-Plex included in an earlier-access program: “We’ve formerly labored using the HD-1 Analyzer and also have been consistently impressed using the versatility from the Simoa technology and also the depth this approach provides.
“It enables us to identify biomarkers we couldn’t formerly see along with other approaches. Now, like a benchtop instrument that provides multiplexing abilities, we are able to optimize our in-house laboratory robotics and liquid handlers to achieve significant economies of scale, including sample upkeep and throughput, which will help with this main point here costs,” stated Rob McDade, Ph.D., President at Myriad.
The SR-Plex benchtop instrument is going to be displayed the very first time at generation x Dx Summit in Washington, D.C., August 15-17, 2017. On August 15 at 1:00 p.m. ET, Kevin Hrusovsky may lead a lunch presentation entitled “Convergence of Next-gen Digital Health insurance and Biomarker Technologies is Enabling a change to Asymptomatic Medicine and Precision Health”.
Mr. Hrusovsky may also join leaders from bioMérieux and Novarum to sign up inside a keynote Technology Panel on August 16 at 12:15 p.m. ET entitled “Disruptive Technologies in Lab Medicine”.
Quanterix will initiate an earlier-access program for that SR-Plex starting in Q4 2017 and expects full accessibility to the merchandise in Q1 2018. The SR-Plex is perfect for research only use and never to be used in diagnostic procedures.
Source: Company Pr Release